Cardiovascular complications in patients with advanced prostatic cancer treated by means of orchiectomy or polyestradiol phosphate

Objective. To evaluate the cardiovascular ( CV) complications associated with orchiectomy ( OE) and parenteral polyestradiol phosphate ( PEP) therapy ( 240 mg/ month), taking into account the effect of pretreatment diseases and pretreatment medication. Material and methods. A total of 244 T3 - 4 M0 patients and 200 T1 - 4 M1 patients were randomized to either OE or PEP therapy. The two groups of patients were analyzed separately. The follow- up period was 36 months. The effect of pretreatment vascular and other diseases and pretreatment medication which may be associated with a risk of CV complications was evaluated. Results. In the T3 -/ 4 M0 patients, the treatment ( PEP versus OE) and the presence of pretreatment vascular diseases were statistically significantly associated with a risk of CV complications ( p = 0.01 and 0.003, respectively). In the T1 - 4 M1 patients, such an association was not found. No association was observed between pretreatment medication and CV complications. There was no difference in progression- free time between the therapy groups in either the T3 - 4 M0 or T1 - 4 M1 patients. Conclusion. In patients with locally advanced prostatic cancer, PEP therapy is associated with a statistically significantly higher risk of CV complications compared to OE.